Table 4 Clinical features, laboratory characteristics, and outcome in relation to total TCR-B aberrations and TCRA/D abnormality
Parameters | TCR-B aberrations | p-value | TCRA/D abnormality | p-value | |||
|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | ||||
Age | Median (range) | 6 (1–18) | 6.5 (3–17) | 0.676 | 6 (2–18) | 6.5 (1–18) | 0.629 |
Hemoglobin (g/dl) | Median (range) | 7.6 (4–15) | 8 (5–11) | 0.760 | 7.2 (4–12) | 8.4 (5–14.5) | 0.338 |
Platelets’ count (× 109/L) | Median (range) | 48 (8–693) | 48 (9–224) | 0.508 | 50 (9–693) | 44.5 (8–224) | 0.429 |
WBC (× 109/L) | Median (range) | 269 (2–967) | 75 (2–883) | 0.022 | 230 (2–967) | 144 (3–746) | 0.177 |
PB blast% | Median (range) | 83 (0–99) | 80 (0–99) | 0.349 | 80 (0–99) | 83 (0–97) | 0.847 |
BM blast% | Median (range) | 90 (0–99) | 85 (20–97) | 0.104 | 90 (0–99) | 88.5 (28–98) | 0.238 |
Sex | Male | 35 (70.0%) | 9 (69.2%) | 0.957 | 20 (60.6%) | 24 (80.0%) | 0.094 |
Female | 15 (30.0%) | 4 (30.8%) | 13 (39.4%) | 6 (20.0%) | |||
Initial CNS | CNSI | 37 (74%) | 11 (84.6%) | 0.003 | 4 (12.1%) | 5 (16.7%) | 0.346 |
23 (69.7%) | 16 (53.3%) | ||||||
TLP | 11 (22%) | 2 (15.4%) | 6 (18.2%) | 7 (23.3%) | |||
CNSIII | 2 (4%) | 0 (0.0%) | 0 (0.0%) | 2 (6.7%) | |||
BM cellularity | Hypercellular | 40 (80%) | 11 (84.6%) | 0.706 | 27 (81.8%) | 24 (80.0%) | 0.845 |
Normocellular | 10 (20%) | 2 (15.4%) | 6 (18.2%) | 6 (20.0%) | |||
CD34 | Negative | 40 (80%) | 13 (100%) | 0.105 | 30 (90.9%) | 23 (76.7%) | 0.172 |
Positive | 10 (20%) | 0 (0.0%) | 3 (9.1%) | 7 (23.3%) | |||
ETP | Negative | 45 (90%) | 11 (84.6%) | 0.627 | 32 (97.0%) | 24 (80.0%) | 0.047 |
Positive | 5 (10%) | 2 (15.4%) | 1 (3.0%) | 6 (20.0%) | |||
MCN | Normal | 39 (78.0%) | 7 (53.8%) | 0.081 | 29 (87.9%) | 17 (56.7%) | 0.006 |
Hypodiploidy | 5 (10.0%) | 1 (7.7%) | 3 (9.1%) | 3 (10.0%) | |||
Hyperdiploidy | 6 (12.0%) | 5 (38.5%) | 1 (3.0%) | 10 (33.3%) | |||
Other chromosomal abnormalities | Negative | 40 (80.0%) | 5 (38.5%) | 0.003 | 25 (75.8%) | 20 (66.7%) | 0.425 |
Positive | 10 (20%) | 8 (61.5%) | 8 (24.2%) | 10 (33.3%) | |||
Complex | Negative | 44 (88.0%) | 9 (69.2%) | 0.099 | 29 (87.9%) | 24 (80.0%) | 0.393 |
Positive | 6 (12.0%) | 4 (30.8%) | 4 (12.1%) | 6 (20.0%) | |||
MRD15 | < 0.01 | 6 (17.1%) | 3 (33.3%) | 0.360 | 6 (23.1%) | 3 (16.7%) | 0.716 |
≥ 0.01 | 29 (82.9%) | 6 (66.7%) | 20 (76.9%) | 15 (83.3%) | |||
MRD42 | < 0.01 | 11 (29.7%) | 4 (80.0%) | 0.047 | 9 (42.9%) | 6 (28.6%) | 0.520 |
≥ 0.01 | 26 (70.3%) | 1 (20.0%) | 12 (57.1%) | 15 (71.4%) | |||
Relapse | Negative | 42 (84.0%) | 13 (100%) | 0.188 | 27 (81.8%) | 28 (93.3%) | 0.261 |
Positive | 8 (16.0%) | 0 (0.0%) | 6 (18.2%) | 2 (6.7%) | |||
Death | Negative | 30 (60.0%) | 6 (46.2%) | 0.531 | 17 (51.5%) | 19 (63.3%) | 0.446 |
Positive | 20 (40.0%) | 7 (53.8%) | 16 (48.5%) | 11 (36.7%) | |||
Early death | Negative | 44 (88.0%) | 8 (61.5%) | 0.040 | 27 (81.8%) | 25 (83.3%) | 0.478 |
Positive | 6 (12.0%) | 5 (38.5%) | 6 (18.2%) | 5 (16.7%) | |||